Development Pipeline

This is the development pipeline As of Oct 27, 2020.

1. Oncology (OPDIVO)

As of Oct 27, 2020

Product name
(Generic name)
Mechanism Target disease Development
stage
Country/
Region
Licensor
F
i
l
i
n
g
A
p
p
r
o
v
a
l
Opdivo Injection (Nivolmub) Anti-PD-1 antibody Melanoma(1st)
 
 
 
 
 
JP・KR・TW In-house
(Co-developed with Bristol Myers Squibb)
Melanoma (Adjuvant therapy)
 
 
 
 
 
JP・KR・TW
Non-small cell lung cancer (2nd~)
 
 
 
 
 
JP・KR・TW
Non-small cell lung cancer (1st)
 
 
 
 
 
JP
 
 
 
 
 
KR・TW
Renal cell carcinoma (2nd~)
 
 
 
 
 
JP・KR・TW
Renal cell carcinoma (1st)
 
 
 
 
 
JP・KR・TW
Hodgkin’s lymphoma
 
 
 
 
 
JP・KR・TW
Head and neck cancer
 
 
 
 
 
JP・KR・TW
Gastric cancer (3rd)
 
 
 
 
 
JP・KR・TW
Gastric cancer (1st)
 
 
 
 
 
JP
 
 
 
 
 
KR・TW
Malignant pleural mesothelioma
 
 
 
 
 
JP
Colorectal cancer(MSI-High)
 
 
 
 
 
JP・TW
Esophageal cancer
 
 
 
 
 
JP・KR・TW
Gastro-esophageal junction cancer and esophageal cancer
 
 
 
 
 
JP・KR・TW
Hepatocellular carcinoma
 
 
 
 
 
JP・KR
 
 
 
 
 
TW
Glioblastoma
 
 
 
 
 
JP
Urothelial cancer
 
 
 
 
 
JP
 
 
 
 
 
KR・TW
Ovarian cancer
 
 
 
 
 
JP・KR・TW
Bladder cancer
 
 
 
 
 
JP・KR・TW
Cervix carcinoma, Uterine body cancer, Soft tissue sarcoma
 
 
 
 
 
JP
Central nervous system lymphoma, Primary Testicular Lymphoma
 
 
 
 
 
JP
Pancreatic cancer
 
 
 
 
 
JP・KR・TW
Virus positive/negative solid carcinoma
 
 
 
 
 
JP・KR・TW
Biliary tract cancer
 
 
 
 
 
JP
Prostate cancer
 
 
 
 
 
JP・KR・TW

2. Oncology (Other than OPDIVO)

As of Oct 27, 2020

Product name
(Generic name)
Mechanism Target disease Development
stage
Country/
Region
Licensor
F
i
l
i
n
g
A
p
p
r
o
v
a
l
Yervoy Injection★
(Ipilimumab)
Anti-CTLA-4 antibody Melanoma
 
 
 
 
 
JP・KR・TW BMS
Renal cell carcinoma
 
 
 
 
 
JP・KR・TW
Non-small cell lung cancer
 
 
 
 
 
JP
 
 
 
 
 
KR・TW
Colorectal cancer(MSI-High)
 
 
 
 
 
JP・TW
Head and neck cancer
 
 
 
 
 
JP・KR・TW
Gastric cancer
 
 
 
 
 
JP・KR・TW
Malignant pleural mesothelioma
 
 
 
 
 
JP
Esophageal cancer
 
 
 
 
 
JP・KR・TW
Urothelial cancer
 
 
 
 
 
JP・KR・TW
Hepatocellular carcinoma
 
 
 
 
 
JP・KR・TW
Virus positive/negative solid carcinoma
 
 
 
 
 
JP・KR・TW
VELEXBRU Tablet/ (Tirabrutinib) Bruton‘s tyrosine kinase (BTK) inhibitor Primary central nervous system lymphoma
 
 
 
 
 
JP In-house
Primary macroglobulinemia Lymphoplasmacytic lymphoma
 
 
 
 
 
JP
ONO-7643/ (Anamorelin) Ghrelin mimetic Cancer cachexia
 
 
 
 
 
JP Helsinn
Braftovi Capsule/ (Encorafenib) BRAF inhibitor Melanoma (BRAF-mutation positive)
 
 
 
 
 
JP Pfizer
 
 
 
 
 
KR
Colorectal cancer (BRAF-mutation positive)
 
 
 
 
 
JP
 
 
 
 
 
KR
Mektovi Tablet/ (Binimetinib) MEK inhibitor Melanoma (BRAF-mutation positive)
 
 
 
 
 
JP Pfizer
 
 
 
 
 
KR
Colorectal cancer (BRAF-mutation positive)
 
 
 
 
 
JP
 
 
 
 
 
KR
Kyprolis Injection/ (Carfilzomib) Proteasome inhibitor Multiple myeloma
 
 
 
 
 
JP Amgen
ONO-7701★
(Linrodostat)
IDO1 inhibitor Bladder cancer
 
 
 
 
 
JP・KR・TW BMS
ONO-7912 (Devimistat) Cancer metabolism inhibitor Pancreatic cancer
 
 
 
 
 
KR Rafael
 
 
 
 
 
JP
Acute myeloid leukemia
 
 
 
 
 
KR
ONO-4686 ★ Anti-TIGIT antibody Solid tumor
 
 
 
 
 
JP BMS
ONO-7807★ Anti-TIM-3 antibody Solid tumor
 
 
 
 
 
JP BMS
ONO-4482★ (Relatlimab) Anti-LAG-3 antibody Melanoma
 
 
 
 
 
JP BMS
ONO-4483★ (Lirilumab) Anti-KIR antibody Solid tumor
 
 
 
 
 
JP BMS
ONO-4578★ PG receptor (EP4) antagonist Solid tumor
 
 
 
 
 
JP In-house
ONO-7475 Axl/Mer inhibitor Solid tumor★
 
 
 
 
 
JP In-house
Acute leukemia
 
 
 
 
 
US
ONO-7911★ (Bempegaldesleukin) PEGylated IL-2 Solid tumor
 
 
 
 
 
JP BMS
ONO-7913 (Magrolimab) Anti-CD47 antibody Solid tumor
 
 
 
 
 
JP Gilead

★Combination with Opdivo.

3. Areas other than Oncology

As of Oct 27, 2020

Product name
(Generic name)
Mechanism Target disease Development
stage
Country/
Region
Licensor
F
i
l
i
n
g
A
p
p
r
o
v
a
l
Coralan Tablet/ ONO-1162 (Ivabradine) HCN channel blocker Chronic heart failure
 
 
 
 
 
JP Servier
Ongentys Capsule/ ONO-2370 (Opicapone) Long acting COMT inhibitor Parkinson’s disease
 
 
 
 
 
JP Bial
Onoact Injection (Landiolol hydrochloride) Short-active selective β1 blocker Tachyarrhythmia associated with sepsis
 
 
 
 
 
JP In-house
Tachyarrhythmia in low cardiac function (Pediatric)
 
 
 
 
 
JP
ONO-5704/SI-613 Hyaluronic acid-NSAID Osteoarthritis
 
 
 
 
 
JP Seikagaku
Enthesopathy
 
 
 
 
 
JP
Orencia SC (Abatacept) T-cell activation inhibitor Prevention of structural damage of joints in rheumatoid arthritis
 
 
 
 
 
JP BMS
Polymyositis/ Dermatomyositis
 
 
 
 
 
JP
Velexbru Tablet/ ONO-4059 (Tirabrutinib) Bruton's tyrosine kinase (BTK) inhibitor Pemphigus
 
 
 
 
 
JP In-house
ONO-7269 FXIa inhibitor Cerebral infarction
 
 
 
 
 
JP In-house
ONO-4685 PD-1×CD3 bispecific antibody Autoimmune disease
 
 
 
 
 
JP In-house
ONO-2808 S1P5 receptor agonist Neurodegenerative disease
 
 
 
 
 
US In-house
ONO-7684 FXIa inhibitor Thrombosis
 
 
 
 
 
US In-house
ONO-2910 Enhancement of Schwann cell differentiation Peripheral nerve disorder
 
 
 
 
 
JP In-house
FOIPAN Protease enzyme inhibitor Novel coronavirus infection (COVID-19)
 
 
 
 
 
JP In-house